Press Releases for IMGN

Press Releases
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial Results
ImmunoGen, Inc. Announces Webcast of Presentation at the 29th Annual Canaccord Adams Global Growth Conference
ImmunoGen Announces Encouraging New Clinical Data with the Company’s IMGN901 Compound in the Treatment of Small-Cell Lung Cancer
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2009 Financial Results
ImmunoGen, Inc. Announces Completion of Public Offering of Common Stock
ImmunoGen, Inc. Announces Exercise of Over-Allotment Option
ImmunoGen, Inc. Prices Public Offering of Common Stock
ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock
ImmunoGen, Inc. Elects to Discontinue Further Internal Development of Its IMGN242 Compound
ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO
ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society for Clinical Oncology Annual Meeting
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2009 Financial Results
SuperNovaStockPicks.Com Releases Special Trade Alerts on Hot Stocks Along With Their Free Service Today: C, MSFT, KIRK, MBND, IMGN, ETFC
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2009 Financial Results
ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research Annual Meeting
ImmunoGen, Inc. Earns Milestone Payment with Genentech’s Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing; Other T-DM1 Progress Reported
ImmunoGen, Inc. Announces Webcast of Presentation at the BIO CEO & Investor Conference 2009
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2009 Financial Results
ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 27, 2009
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2009 Financial Results
ImmunoGen, Inc. Appoints Gregory Perry as Senior Vice President and Chief Financial Officer
ImmunoGen, Inc. Announces Webcast of Presentation at the 27th Annual J.P. Morgan Healthcare Conference
ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual Meeting
ImmunoGen, Inc. Announces Genentech’s Fifth TAP Technology License
ImmunoGen, Inc. Announces Webcast of Panel Session at the RBC Capital Markets 2008 Healthcare Conference
ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
ImmunoGen, Inc. Appoints James J. O'Leary, MD, as Vice President and Chief Medical Officer
ImmunoGen, Inc. Earns $4 Million Milestone Payment with sanofi-aventis' Initiation of a Phase II Trial with AVE1642
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual BioInvestor Forum
ImmunoGen, Inc. Announces Bayer HealthCare Has Licensed Rights to TAP Technology for a Solid Tumor Target
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2009 Financial Results
ImmunoGen, Inc. Announces Presentations at Upcoming EORTC-NCI-AACR Symposium
ImmunoGen, Inc. Announces CEO Succession Plan
ImmunoGen, Inc. to Present at Upcoming Investor Conferences
ImmunoGen, Inc. Announces Webcast of Presentation at the Thomas Weisel Partners Healthcare Conference 2008
ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results
BeaconEquity.com Issues Trade Alerts on Market Movers: IBOT, PWAV, EXTR, CRBC, IMGN, THPW
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2008 Financial Results
ImmunoGen, Inc. Announces Senior Management Promotions
ImmunoGen, Inc. Announces Start of IMGN388 Clinical Testing
ImmunoGen, Inc. Raises $25.0 Million in Registered Direct Offering of Common Stock
ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO
ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with Targeted Anticancer Compounds IMGN242 and AVE1642
ImmunoGen, Inc. Announces Presentations at Upcoming 2008 American Society of Clinical Oncology Annual Meeting - May 26 2008 10:32PM
ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual JMP Securities Research Conference - Jun 1 2008 11:06PM
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2008 Financial Results - Jun 1 2008 11:05PM
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2008 Financial Results
ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research 2008 Annual Meeting